Key Takeaways
MetLife (NYSE: MET) recently navigated its first quarter of 2026 with a performance that delivered both pleasant surprises and notable disappointments, leaving common shareholders with a nuanced outlook. The global insurance giant reported adjusted earnings per share (EPS) of $2.42 for Q1 2026, significantly beating analyst estimates of $2.27 by a robust 6.6%. This strong profit figure was a key highlight, with President and CEO Michel Khalaf emphasizing that the quarter showcased "the full earnings power of MetLife" under its "New Frontier" strategy.
The positive momentum extended to net premiums earned, which reached $12.12 billion, comfortably surpassing Wall Street's consensus of $11.65 billion by 4%. This beat, however, came despite a 6.4% year-over-year decline in net premiums earned. On the other hand, the company's revenue growth proved softer than anticipated, rising only 1.3% year-on-year to $19.07 billion, missing analyst estimates of $19.41 billion by 1.7%. This revenue miss, alongside a significant shortfall in book value per share (BVPS), tempered the overall enthusiasm.
Book value per share stood at $37.92, a substantial 35% miss against analyst estimates of $58.37 and a 7.1% year-on-year decline. This metric, often a critical indicator for insurance companies, suggests underlying pressures despite the strong adjusted earnings. Following the earnings announcement on May 6, 2026, MetLife's stock remained relatively flat at $80.22, reflecting the market's mixed reaction to these divergent results. As of May 22, 2026, the stock trades at $84.06, indicating some recovery but still within a tight range.
Further analysis of the Q1 results reveals an adjusted return on equity (ROE) of 17%, hitting the top end of the company’s 15% to 17% target range, and an improved direct expense ratio of 11.9%, ahead of its 2026 annual target of 12.1%. While net income was $1.1 billion, or $1.74 per share, CFO John McCallion noted that the primary difference from adjusted earnings stemmed from net investment losses, mainly from normal trading activity within the fixed maturity portfolio. These details underscore the complexity of MetLife's financial health, balancing operational efficiency and strong core profitability against investment portfolio fluctuations and slower top-line growth.
MetLife's commitment to shareholder returns and its robust capital position remain a cornerstone of its investment thesis, even amidst mixed quarterly results. In Q1 2026, the company returned a substantial $1.1 billion to shareholders, demonstrating a consistent focus on capital deployment. This figure includes approximately $750 million in share repurchases and about $370 million in common stock dividends. Notably, MetLife continued its buyback activity into April 2026, repurchasing nearly another $200 million of stock, with $1.1 billion remaining on its existing authorization.
This aggressive capital management strategy is supported by a strong liquidity profile. MetLife ended Q1 2026 with $3.9 billion of cash and liquid assets at its holding companies, positioning it comfortably at the top end of its $3 billion to $4 billion target liquidity buffer. This financial flexibility allows the company to navigate market uncertainties and pursue strategic initiatives, such as the recent issuance of $1 billion in subordinated debt, which CEO Michel Khalaf stated supports the balance sheet and provides growth capital.
The board's approval of a 4.4% increase in the common dividend per share, raising it to $0.5925 payable on June 9, 2026, further reinforces MetLife's dedication to income investors. This marks a continuation of a trend, with the company having increased its common stock quarterly dividend at an 8.1% compound annual growth rate since 2011. The dividend yield currently stands at a healthy 2.7%, with a payout ratio of 46.4% based on trailing twelve-month (TTM) EPS of $5.55, indicating ample coverage and sustainability.
Furthermore, MetLife's adjusted book value per common share rose to $57.41 in Q1 2026, up from $55.01 a year earlier, reflecting growth in equity after excluding certain accumulated other comprehensive income items. While the reported book value per share missed estimates, the adjusted figure provides a clearer picture of the company's underlying equity strength. These metrics collectively paint a picture of a financially sound institution that prioritizes returning value to its shareholders, even as it manages various operational and market dynamics.
For income-focused investors, MetLife's preferred shares present a compelling alternative to its common stock, offering higher yields and a preferential claim on earnings and assets. The company's preferred dividends are notably well-covered, with payout ratios often under 4% of adjusted earnings, and potentially dropping to 3% as EPS grows. This strong coverage provides a significant layer of security for preferred shareholders, who typically receive fixed or floating dividend payments before common shareholders.
Consider the MetLife Series F preferred stock (MET.PR.F), which currently trades at approximately $19.25 and offers an attractive yield of 6.15%. This yield is substantially higher than the 2.7% offered by MetLife's common shares, making it particularly appealing in the current interest rate environment. Another example is the floating rate non-cumulative preferred stock, Series A (MET PRA), which confirmed a Q1 2026 dividend of $0.31501229 per share, payable on March 16, 2026. These Series A shares also feature a minimum 4% floor for dividends, with potential for higher yields based on 3-month SOFR rate adjustments.
Preferred stock combines characteristics of both bonds and common stock. Like bonds, they often provide predictable income, usually paid quarterly, and typically have no maturity date. However, like equity, their market price can fluctuate based on interest rates, the issuer's credit rating, and broader market conditions. Preferred shareholders also enjoy a liquidation preference, meaning they rank ahead of common shareholders in the event of a company liquidation, although bondholders still take precedence.
The stability of preferred dividends, backed by MetLife's robust adjusted income and strong balance sheet, makes them a suitable option for investors seeking consistent income with potentially lower volatility compared to common stock. While preferred shares are not without risks, such as interest-rate sensitivity and call risk, MetLife's consistent dividend declarations and solid financial health, including its $3.9 billion in holding company cash, underscore the reliability of these income streams. This makes MetLife's preferred offerings a potentially valuable addition to an income-oriented portfolio, especially when common stock growth prospects appear more uncertain.
Analyst sentiment surrounding MetLife (MET) common shares appears mixed, leaning towards a cautious "Hold" or "Buy" with reservations, particularly concerning its valuation. As of May 24, 2026, Wall Street analysts have a consensus one-year price target of $91.69, representing a potential 9.1% upside from the current price of $84.06. However, individual price targets vary, with some analysts like JPMorgan raising their target to $96 from $95 on May 12, 2026, and Wells Fargo increasing theirs to $95 from $90 on the same day. Conversely, Bank of America lowered its target to $99 from $103 on April 14, 2026, and Mizuho reduced its target to $93 from $100 on April 13, 2026.
According to TickerNerd, out of 18 analysts, 12 rate MetLife as a "Buy," 6 as a "Hold," and 0 as a "Sell." Public.com, however, reports 13 analysts with a consensus "Buy" rating, breaking down to 31% "Strong Buy," 54% "Buy," and 15% "Hold." This divergence highlights the ongoing debate about MetLife's future trajectory. StockStory analysts, for instance, maintain an "Underperform" rating, citing weak sales growth over the last five years and expectations for demand deterioration over the next 12 months. They also point to a declining book value per share over the past five years, despite an estimated strong BVPS growth for the next 12 months.
Valuation is a key point of contention. MetLife currently trades at a price-to-earnings (P/E) ratio of 15.14 based on TTM EPS of $5.55, and a price-to-book (P/B) ratio of 2.01. StockStory argues that at $84.01 per share, MetLife trades at 1.9x forward P/B, which they consider "quite expensive for the weaker revenue growth you get" compared to other insurance companies. Simply Wall St, while noting the stock trades 47.8% below their fair value estimate, also highlights a "high level of debt" as a risk.
The TTM P/S ratio of 0.70 and P/FCF of 3.27 suggest a more reasonable valuation from a sales and cash flow perspective. However, the market's focus on revenue growth and book value per share, particularly the Q1 2026 miss on both, contributes to the cautious stance from some analysts. The consensus price target of $91.69 indicates a modest upside, but the mixed analyst ratings and concerns over valuation suggest that investors should carefully weigh the growth prospects against the current price.
Despite the mixed Q1 2026 results, MetLife's underlying operational segments demonstrated resilience and growth, driven by its "New Frontier" strategy. CEO Michel Khalaf highlighted broad-based growth across operating businesses, favorable underwriting trends, and disciplined capital management. Adjusted earnings were ahead of the prior year in all operating business segments, with top-line growth across nearly all businesses and regions.
The Group Benefits segment saw sales increase by 15%, fueled by strong performance in core and voluntary products. Adjusted premiums, fees, and other revenues for this segment rose 2% year-over-year, or approximately 4% excluding the impact of participating contracts. Persistency improved broadly, particularly in dental, and voluntary product growth achieved double-digit figures. This indicates healthy demand and effective product offerings in a competitive market.
Retirement and Income Solutions (RIS) reported adjusted earnings of $451 million, an 11% increase from the prior year, primarily driven by higher variable investment income and favorable underwriting margins. CFO John McCallion noted that the total investment spread reached 119 basis points, landing at the top end of the company’s 100 to 120 basis point guidance range. While core spread, excluding variable investment income, saw a slight sequential dip of 4 basis points, this was attributed to asset rotation tied to large Q4 pension risk transfer inflows, suggesting strategic portfolio adjustments rather than fundamental weakness.
Internationally, MetLife's operations also performed well. Asia earnings were up a significant 31%, and Latin America and EMEA (Europe, Middle East, and Africa) delivered solid gains. EMEA adjusted earnings, for instance, rose 33% to $110 million, with adjusted premiums, fees, and other revenues increasing 15% on a constant currency basis. Khalaf attributed this international success to strong sales growth over several years translating into premium and earnings expansion. MetLife Investment Management (MIM) also reported adjusted earnings of $47 million, up from $28 million a year earlier, following the first fully integrated quarter after the PineBridge acquisition. This segment's elevation to a standalone reportable segment under new market-based fee arrangements is expected to enhance visibility and measurability of its fee-driven business.
While MetLife's Q1 2026 performance showcased operational strengths and robust capital returns, several risks and challenges loom on the horizon that investors should carefully monitor. One significant concern revolves around the company's exposure to commercial real estate (CRE), particularly office properties. Although MetLife has stated that potential losses would take years to materialize and could be absorbed, the insurer is reportedly overweight in this sector. Concerns about CRE losses and potential interest rate cuts continue to cast a shadow over the broader life insurance industry, including MetLife.
Another area of vigilance is the company's revenue growth trajectory. Despite the Q1 2026 adjusted EPS beat, the 1.3% year-on-year revenue growth and the 1.7% miss against analyst estimates raise questions about MetLife's ability to consistently expand its top line. StockStory analysts have specifically highlighted weak revenue growth over the last five years and anticipate a deterioration in demand over the next 12 months, which could pressure future earnings. The decline in book value per share (BVPS) over the past five years, despite an estimated strong BVPS growth for the next 12 months, also points to underlying structural challenges that need to be addressed.
Furthermore, the impact of interest rates remains a double-edged sword for insurers. While higher rates have allowed MetLife to reprice its investment portfolio at more favorable rates and sell more spread products, potential future rate cuts could compress investment margins. Analysts have also noted an estimated headwind of $300-325 million to Retirement and Income Solutions (RIS) earnings as interest rate caps roll off, along with expected base spread compression leading to further EPS declines of around $0.20 per share. This sensitivity to interest rate movements necessitates close attention to macroeconomic trends and Federal Reserve policy.
Finally, the competitive landscape and the ongoing need for digital transformation pose continuous challenges. While MetLife has invested over $3.2 billion over five years to modernize its technology ecosystem and leverage AI for improved customer service and productivity, maintaining a competitive edge in a rapidly evolving financial services industry requires sustained innovation and investment. The company's ability to effectively manage these risks, particularly its CRE exposure and revenue growth, will be crucial in determining its long-term performance and investor appeal.
MetLife's Q1 2026 results painted a complex picture, showcasing strong adjusted earnings and robust capital returns alongside softer revenue growth and a notable miss on book value per share. While the company's preferred shares offer an attractive and well-covered income stream for risk-averse investors, common shares present a more nuanced opportunity. Investors should weigh MetLife's operational strengths and commitment to shareholder value against ongoing concerns regarding revenue growth, commercial real estate exposure, and interest rate sensitivity.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
